Tumor Immune-Infiltrate Landscape After Chemo-Radiotherapy in a Case Series of Patients with Non-small Cell Lung Cancer: Pretreatment Predictors and Correlation With Outcome.
chemo-radiotherapy
immunotherapy
locally advanced NSCLC
platelet-to-lymphocyte ratio
tumor immune microenvironment
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
04 03 2022
04 03 2022
Historique:
received:
19
08
2021
accepted:
28
10
2021
entrez:
31
5
2022
pubmed:
1
6
2022
medline:
3
6
2022
Statut:
ppublish
Résumé
Data on tumor immune-milieu after chemo-radiation (CT-RT) are scarce. Noninvasive tools are needed to improve the treatment of non-small cell lung cancer (NSCLC), especially in the locally advanced (LA) setting. We collected a series of superior-sulcus (SS)- patients with NSCLC referred to our Institute (2015-2019), eligible for a preoperative CT-RT. We characterized tumor-infiltrating immune cells (TIICs), determined PD-L1-TPS and the residual viable tumor cells (RVTC). Radiological and metabolic responses were reviewed. We calculated pre-surgery neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR). Eight patients were included. Radiological responses were 6 disease stabilities (SD) and 2 partial responses (PR). Metabolic responses were 4 SD and 4 PR. CD68+-TIICs were correlated with metabolic response and lower RVTC. CD68+-TIICs were associated with higher PLR. Higher PLR values seemed linked with lower RVTC. These preliminary results could be useful for consolidation treatment selection for patients with LA-NSCLC without evaluable baseline PD-L1 and higher PLR values.
Identifiants
pubmed: 35641202
pii: 6518014
doi: 10.1093/oncolo/oyab047
pmc: PMC8895738
doi:
Substances chimiques
B7-H1 Antigen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e199-e202Informations de copyright
© The Author(s) 2022. Published by Oxford University Press.
Références
Nat Immunol. 2015 Oct;16(10):1005-7
pubmed: 26343538
Oncotarget. 2015 Dec 8;6(39):42053-66
pubmed: 26544728
Appl Immunohistochem Mol Morphol. 2018 Oct;26(9):611-619
pubmed: 28422766
Ann Oncol. 2017 Jul 1;28(suppl_4):iv1-iv21
pubmed: 28881918
Int J Radiat Oncol Biol Phys. 2021 May 1;110(1):35-52
pubmed: 30836168
Lung Cancer. 2014 Apr;84(1):39-44
pubmed: 24513263
J Thorac Oncol. 2020 May;15(5):709-740
pubmed: 32004713
J Thorac Oncol. 2021 May;16(5):860-867
pubmed: 33476803
Lung Cancer. 2010 May;68(2):228-33
pubmed: 19632000
Lung Cancer. 2019 Aug;134:202-209
pubmed: 31319982